Lupin Manufacturing Solutions: Empagliflozin API gets CADIFA approval from ANVISA, Brazil
Lupin Manufacturing Solutions has announced thatEmpagliflozin API, manufactured at its Vizag facility, has received CADIFA approval from ANVISA, Brazil. Empagliflozin is a proven SGLT-2 inhibitor used in type-2 diabetes care, helping patients control blood sugar and reduce long term complications. Lupin Manufacturing Solutions (LMS) is a wholly owned subsidiary of Lupin. The company specializes in manufacturing and supplying high-quality, cost-effective Active Pharmaceutical Ingredients (APIs). Read also:Lupin wins USFDA nod for Risperidone for extended-release injectable suspension for schizophrenia
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!